TP53 and cancer: Since mutant P53 is stabilized by the heat shock protein HSP90, usually over-expressed in cancer cells (55), several HSP90 inhibitors, such as 17-AAG or Ganetespib, have been tested as anticancer molecules and their ability to trigger mutant P53 degradation has been demonstrated (56).